Nadine T Hillock
Overview
Explore the profile of Nadine T Hillock including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
23
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hillock N, Cheng A, Bowskill A
JAC Antimicrob Resist
. 2025 Mar;
7(1):dlae216.
PMID: 40041154
Background: Ensuring timely and equitable access to effective and optimal antimicrobials is crucial for optimal patient care, to minimize the use of less appropriate treatment options and reduce the risk...
2.
Maher D, Sluggett J, Soriano J, Hull D, Hillock N
J Am Med Dir Assoc
. 2024 Jul;
25(9):105144.
PMID: 38991651
Objectives: To explore antimicrobial management processes in Australian residential aged care facilities (RACFs), including antimicrobial prescribing, supply, administration, and documentation to inform surveillance activities. Design: Voluntary, online cross-sectional survey. Setting...
3.
Hillock N, Campbell D, Nelson R, Teoh A, Tan J, Smitham P
ANZ J Surg
. 2023 Jan;
93(6):1467-1470.
PMID: 36680316
No abstract available.
4.
Hillock N, Merlin T, Turnidge J, Karnon J
Appl Health Econ Health Policy
. 2022 Apr;
20(4):479-486.
PMID: 35368230
Due to the increasing threat to public health and the economy, governments internationally are interested in models to estimate the future clinical and economic burden of antimicrobial resistance (AMR) and...
5.
Hillock N, Connor E, Wilson C, Kennedy B
JAC Antimicrob Resist
. 2021 Jul;
3(1):dlab017.
PMID: 34223094
Background: In 2020 the Australian Priority Antibacterial List (PAL) was developed to support national surveillance of antibacterial usage. Objectives: To compare the WHO AwaRe classification system with the Australian PAL...
6.
Hillock N, Merlin T, Karnon J, Turnidge J, Eliott J
JAC Antimicrob Resist
. 2021 Jul;
2(2):dlaa023.
PMID: 34222987
Background: There is a disparity in the economic return achievable for antimicrobials compared with other drugs because of the need for stewardship. This has led to a decline in pharmaceutical...
7.
Hillock N, Merlin T, Karnon J, Turnidge J, Eliott J
Int J Technol Assess Health Care
. 2020 Nov;
37:e28.
PMID: 33138869
Background: The frameworks used by Health Technology Assessment (HTA) agencies for value assessment of medicines aim to optimize healthcare resource allocation. However, they may not be effective at capturing the...
8.
Hillock N, Karnon J, Turnidge J, Merlin T
Infect Dis Health
. 2020 Jan;
25(2):82-91.
PMID: 31911133
Objective: To identify and estimate the usage of unregistered antimicrobial drugs in Australian clinical practice. Methods: A descriptive pharmaco-epidemiological study, utilising three data sources: analysis of Special Access Scheme (SAS)...
9.
Hillock N, Paradiso L, Turnidge J, Karnon J, Merlin T
Aust Health Rev
. 2019 Jul;
44(2):263-269.
PMID: 31272525
Objective Increasing antimicrobial resistance and a concurrent paucity of new antimicrobials marketed increases the risk that patients will develop infections resistant to currently available drugs. This study aimed to determine...
10.
Hillock N, Heard S, Kichenadasse G, Hill C, Andrews J
Asia Pac J Clin Oncol
. 2016 Dec;
13(5):e284-e290.
PMID: 27981760
Objective: To review the outcomes of metastatic melanoma patients treated with infliximab for severe steroid-refractory colitis secondary to ipilimumab therapy. Background: Immune-related colitis is a known potential adverse effect of...